Ironwood Pharmaceuticals, Inc.
IRWDHealthcare|Drug Manufacturers - Specialty & Generic|US
$4.39
+0.36 (+8.93%)
DCF Value
$5.89
Cash / Share
$0.52
Clinical Trials (42)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05796388 A Study of Virtual Reality and Linaclotide for IBS-C | Irritable Bowel Syndrome With Constipation | N/A | Recruiting | 65 | RCT, Double-blind | — |
| NCT02590432 An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation | Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | P4 | Completed | 828 | RCT, Open-label | Linaclotide |
| NCT03226899 A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment | Gout, Chronic Kidney Disease (CKD) | P4 | Terminated | 242 | RCT, Double-blind | Lesinurad, XOI, Placebo, colchicine, corticosteroids |
| NCT02837783 A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome Characterized by Constipation | P4 | Terminated | 20 | RCT, Double-blind | Linaclotide, Placebo |
| NCT00730015 Trial of Linaclotide in Patients With Chronic Constipation | Chronic Constipation | P3 | Completed | 643 | RCT, Double-blind | Matching Placebo, Linaclotide |
| NCT00938717 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome With Constipation | P3 | Completed | 805 | RCT, Double-blind | Linaclotide or Matching Placebo |
| NCT02291679 Trial of Linaclotide in Patients With Chronic Idiopathic Constipation | Chronic Idiopathic Constipation | P3 | Completed | 1,223 | RCT, Double-blind | Linaclotide, Matching Placebo |
| NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | P3 | Completed | 123 | RCT, Double-blind | Placebo for Linaclotide, Linaclotide |
| NCT04026113 Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) | Functional Constipation, Irritable Bowel Syndrome With Constipation | P3 | Completed | 438 | RCT, Double-blind | Linaclotide, Placebo |
| NCT00948818 Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | P3 | Completed | 803 | RCT, Double-blind | Linaclotide 290 micrograms, Matching placebo |
| NCT00730171 An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome With Constipation, Chronic Constipation | P3 | Completed | 1,743 | Open-label | Linaclotide |
| NCT04166058 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C | Irritable Bowel Syndrome With Constipation, Functional Constipation | P3 | Completed | 381 | Open-label | Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) |
| NCT00765882 Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation | Chronic Constipation | P3 | Completed | 633 | RCT, Double-blind | Linaclotide 290 micrograms, Linaclotide 145 micrograms, Placebo |
| NCT00765999 An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Chronic Constipation, Irritable Bowel Syndrome With Constipation | P3 | Completed | 1,559 | Open-label | Linaclotide |
| NCT01642914 Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating | Chronic Constipation, Constipation | P3 | Completed | 487 | RCT, Double-blind | Linaclotide 290 micrograms, Linaclotide 145 micrograms, Matching placebo |
| NCT03561883 Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Gastroesophageal Reflux Disease (GERD) | P3 | Completed | 609 | RCT, Double-blind | IW-3718, placebo, Standard-dose PPIs QD |
| NCT01880424 A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome With Constipation (IBS-C) | P3 | Completed | 1,722 | RCT, Double-blind | Placebo, Linaclotide |
| NCT03573908 A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome Characterized by Constipation | P3 | Completed | 614 | RCT, Double-blind | Linaclotide, Placebo |
| NCT03561090 A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) | Gastroesophageal Reflux Disease (GERD) | P3 | Terminated | 495 | RCT, Double-blind | IW-3718, placebo, Standard-dose PPIs QD |
| NCT00404001 Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia | Hypercholesterolemia | P2 | Completed | 150 | RCT, Double-blind | MD-0727 |
| NCT00306748 Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation | Constipation | P2 | Completed | 40 | RCT, Double-blind | MD-1100 Acetate |
| NCT04110145 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation | Functional Constipation | P2 | Completed | 35 | RCT, Double-blind | Linaclotide, Placebo |
| NCT01107236 Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction | Healthy | P2 | Completed | 90 | RCT, Double-blind | IW-6118, Matching Placebo, Naproxen Sodium |
| NCT02270983 Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain | Opioid-Induced Constipation | P2 | Completed | 254 | RCT, Double-blind | Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo |
| NCT00258193 Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS | Irritable Bowel Syndrome | P2 | Completed | 36 | RCT, Double-blind | MD-1100 Acetate |
| NCT02030925 Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors | Gastroesophageal Reflux | P2 | Completed | 93 | RCT, Double-blind | IW-3718, Matching Placebo |
| NCT02637557 A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) | Gastroesophageal Reflux Disease | P2 | Completed | 282 | RCT, Double-blind | IW-3718, Matching Placebo, PPI |
| NCT01712412 Phase 2a Study of IW-9179 to Treat Functional Dyspepsia | Dyspepsia, Functional Gastrointestinal Disorders | P2 | Terminated | 10 | RCT, Double-blind | IW-9179, Placebo |
| NCT02559817 A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome With Constipation | P2 | Terminated | 101 | RCT, Double-blind | Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo |
| NCT02289846 Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) | Diabetic Gastroparesis | P2 | Completed | 90 | RCT, Double-blind | IW-9179, Matching Placebo |
| NCT00402337 Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation | Chronic Constipation | P2 | Completed | 310 | RCT, Double-blind | linaclotide acetate, Matching placebo |
| NCT05740007 A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis, Bladder Pain Syndrome | P2 | Terminated | 98 | RCT, Double-blind | IW-3300 rectal foam, Placebo |
| NCT02559570 A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) | Functional Constipation in Children Ages 6-17 Years | P2 | Completed | 173 | RCT, Double-blind | Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg |
| NCT02559206 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome With Constipation | P2 | Completed | 759 | RCT, Double-blind | Linaclotide, Matching Placebo |
| NCT05760313 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide | Functional Constipation | P2 | Completed | 19 | RCT, Double-blind | Linaclotide, Placebo |
| NCT03931785 A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea (IBS-D) | P2 | Completed | 515 | RCT, Double-blind | MD-7246, Placebo |
| NCT00460811 Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome With Constipation | P2 | Completed | 420 | RCT, Double-blind | Linaclotide Acetate, Matching placebo |
| NCT03856970 Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers | Healthy Volunteers | P1 | Completed | 87 | Open-label | Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718 |
| NCT05188261 A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | IW-3300, Placebo |
| NCT05362695 A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 18 | RCT, Double-blind | IW-3300, Placebo |
| NCT02144376 MRI and Microbiota Analysis in Constipation | Constipation | N/A | Completed | 24 | RCT, Double-blind | — |
| NCT01805999 Ispaghula and Colonic Water Content | Healthy | N/A | Completed | 15 | RCT, Double-blind | — |